| Literature DB >> 36186562 |
Kenta Morita1, Kanon Nishimura1, Shota Yamamoto1, Natsumi Shimizu1, Tomoko Yashiro1, Ryoko Kawabata1, Takashi Aoi2, Atsuo Tamura3, Tatsuo Maruyama1.
Abstract
Cell-selective killing using molecular self-assemblies is an emerging concept for cancer therapy. Reported molecular self-assemblies are triggered by hydrolysis of well-designed molecules inside or outside cancer cells. This hydrolysis can occur in cancer and normal cells because of the abundance of water in living systems. Here, we report the in situ synthesis of a self-assembling molecule using a tyrosine kinase overexpressed in cancer cells. We designed a tyrosine-containing peptide amphiphile (C16-E4Y) that is transformed into a phosphorylated peptide amphiphile (C16-E4pY) by the overexpressed tyrosine kinase. Phosphorylation of C16-E4Y promoted self-assembly to form nanofibers in cancer cells. C16-E4Y exhibited selective cytotoxicity toward cancer cells overexpressing the tyrosine kinase. Self-assembled C16-E4pY induced endoplasmic reticulum stress that caused apoptotic cell death. Animal experiments revealed that C16-E4Y has antitumor activity. These results show that an enzyme overexpressed in cancer cells is available for intracellular synthesis of an antitumor self-assembling drug that is cell-selective.Entities:
Year: 2022 PMID: 36186562 PMCID: PMC9516706 DOI: 10.1021/jacsau.2c00301
Source DB: PubMed Journal: JACS Au ISSN: 2691-3704
Figure 1(a) Selective killing of cancer cells based on the self-assembly of a phosphorylated peptide amphiphile synthesized by a tyrosine kinase overexpressed in cancer cells. (b) Molecular structures of the peptide amphiphile (C16-E4Y) and its phosphorylated form (C16-E4pY).
Figure 2(a, c) Gelation tests of C16-E4Y and C16-E4pY solutions. Phosphate-buffered saline supplemented with 0.95 mM Ca2+, and 0.49 mM Mg2+ was used. (b, d) Transmission electron microscope (TEM) observations of these solution.
Figure 3(a) Tyrosine kinase activity of the various cell lines tested. (b) Cytotoxicity of C16-E4Y toward the various cell lines tested. (c) Effect of EGFR inhibitors (afatinib and erlotinib, 200 nM) on the cytotoxicity of C16-E4Y 0.025 wt % to A431 cells (*p < 0.01). Cell viability without any additives (C16-E4Y and inhibitors) was taken as 100%.
Figure 4CLSM images of A431 cells after incubation with NBD-C8-E4Y (0.001 wt %, green) and C16-E4Y (0.05 wt %) for 24 h. The cells were stained with ER-tracker (red). Scale bar: 50 μm.
Figure 5(a) Effect of C16-E4Y on A431 tumor growth by local injection into the tumor in mice (*p < 0.05). (b) Bodyweight change of mice during the administration experiments. n = 6.